VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis

被引：36

作者：

Low, Sarah ^{[1
]}

Wu, Haixia ^{[1
]}

Jerath, Kavita ^{[1
,5
]}

Tibolla, Annette ^{[2
]}

Fogal, Birgit ^{[2
]}

Conrad, Rebecca ^{[2
]}

MacDougall, Margit ^{[2
,6
]}

Kerr, Steven ^{[2
]}

Berger, Valentina ^{[2
]}

Dave, Rajvee ^{[2
]}

Villalona, Jorge ^{[2
]}

Pantages, Lynn ^{[2
]}

Ahlberg, Jennifer ^{[3
]}

Li, Hua ^{[3
]}

Van Hoorick, Diane ^{[4
,10
]}

Ververken, Cedric ^{[4
,7
]}

Broadwater, John ^{[2
]}

Waterman, Alisa ^{[2
,8
]}

Singh, Sanjaya ^{[1
,9
]}

Kroe-Barrett, Rachel ^{[1
]}

机构：

[1] Boehringer Ingelhe Pharmaceut Inc, Biotherapeut Mol Discovery, 900 Ridgebury Rd, Ridgefield, CT 06877 USA

[2] Boehringer Ingelhe Pharmaceut Inc, Cardiometab Dis Res, Ridgefield, CT 06877 USA

[3] Boehringer Ingelhe Pharmaceut Inc, Biotherapeut Pharmacokinet, Ridgefield, CT 06877 USA

[4] Ablynx Sanofi Co, Project Management, Zwijnaarde, Belgium

[5] Merck, West Point, PA USA

[6] Vascumab LLC, Branford, CT USA

[7] Confo Therapeut NV, Technol Pk 94, B-9052 Ghent, Belgium

[8] FreeThink Technol Inc, Branford, CT USA

[9] Janssen Pharmaceut, Spring House, PA USA

[10] eTheRNA, Niel, Belgium

来源：

MABS | 2020年 / 12卷 / 01期

关键词：

VHH Antibodies; GPCR; atherosclerosis; BI; 655088; biophysical assessment; pharmacokinetic profile; humanization; FRACTALKINE; IDENTIFICATION; FRAGMENTS; BINDING; DISEASE;

D O I：

10.1080/19420862.2019.1709322

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

CX3CR1 has been identified as a highly attractive target for several therapeutic interventions. Despite this potential, no potent antagonists, either small molecule or monoclonal antibody, have been identified. Here we describe the lead finding and engineering approach that lead to the identification of BI 655088, a potent biotherapeutic antagonist to CX3CR1. BI 655088 is a potent CX3CR1 antagonist that, upon therapeutic dosing, significantly inhibits plaque progression in the standard mouse model of atherosclerosis. BI 655088 represents a novel and highly selective biotherapeutic that could reduce inflammation in the atherosclerotic plaque when added to standard of care treatment including statins, which could result in a significant decrease in atherothrombotic events in patients with existing cardiovascular disease.

引用

页数：12

共 50 条

[1] Pharmacological Inhibition of the Chemokine Receptor, CX3CR1, Reduces Atherosclerosis in Mice
Poupel, Lucie
Boissonnas, Alexandre
Hermand, Patricia
Dorgham, Karim
Guyon, Elodie
Auvynet, Constance
Saint Charles, Flora
Lesnik, Philippe
Deterre, Philippe
Combadiere, Christophe
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2013, 33 (10) : 2297 - 2305
[2] Fractalkine/CX3CR1 and atherosclerosis
Liu, Hong
Jiang, Deqian
CLINICA CHIMICA ACTA, 2011, 412 (13-14) : 1180 - 1186
[3] Activation of the human chemokine receptor CX3CR1 regulated by cholesterol
Lu, Minmin
Zhao, Wenli
Han, Shuo
Lin, Xiaowen
Xu, Tingyu
Tan, Qiuxiang
Wang, Mu
Yi, Cuiying
Chu, Xiaojing
Yang, Weibo
Zhu, Ya
Wu, Beili
Zhao, Qiang
SCIENCE ADVANCES, 2022, 8 (26)
[4] Role of the CX3C chemokine receptor CX3CR1 in the pathogenesis of atherosclerosis after aortic transplantation
Rowinska, Zuzanna
Koeppel, Thomas A.
Sanati, Maryam
Schelzig, Hubert
Jankowski, Joachim
Weber, Christian
Zernecke, Alma
Liehn, Elisa A.
PLOS ONE, 2017, 12 (02):
[5] Icariin inhibits atherosclerosis progress in Apoe null mice by downregulating CX3CR1 in macrophage
Wang, Yao
Wang, Yun-Shan
Song, Shu-Liang
Liang, Hao
Ji, Ai-Guo
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 470 (04) : 845 - 850
[6] Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis
McDermott, DH
Halcox, JPJ
Schenke, WH
Waclawiw, MA
Merrell, MN
Epstein, N
Quyyumi, AA
Murphy, PM
CIRCULATION RESEARCH, 2001, 89 (05) : 401 - 407
[7] Role of chemokine CX3CL1 in progression of multiple myeloma via CX3CR1 in bone microenvironments
Wada, Akinori
Ito, Aya
Iitsuka, Hirofumi
Tsuneyama, Koichi
Miyazono, Takayoshi
Murakami, Jun
Shibahara, Naotoshi
Sakurai, Hiroaki
Saiki, Ikuo
Nakayama, Takashi
Yoshie, Osamu
Koizumi, Keiichi
Sugiyama, Toshiro
ONCOLOGY REPORTS, 2015, 33 (06) : 2935 - 2939
[8] Effect of Chemokine Receptor CX3CR1 Deficiency in a Murine Model of Respiratory Syncytial Virus Infection
Johnson, Crystal H.
Miao, Congrong
Blanchard, Elisabeth G.
Caidi, Hayat
Radu, Gertrud U.
Harcourt, Jennifer L.
Haynes, Lia M.
COMPARATIVE MEDICINE, 2012, 62 (01) : 14 - 20
[9] Association of polymorphisms in the chemokine receptor CX3CR1 gene with coronary artery disease
Matzhold, Eva M.
Trummer, Olivia
Gruenbacher, Gerda
Zulus, Barbara
Boehm, Bernhard O.
Maerz, Winfried
Renner, Wilfried
CYTOKINE, 2009, 47 (03) : 224 - 227
[10] Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway
Stavros Apostolakis
Demetrios Spandidos
Acta Pharmacologica Sinica, 2013, 34 : 1251 - 1256

← 1 2 3 4 5 →